Current drug-specific reversal strategies and novel agents under development
| Drug | Drug-specific reversal strategy | Agents likely to be available in the future |
|---|---|---|
| Vitamin K antagonists | Vitamin K, four-factor PCC | |
| Unfractionated heparin | Protamine sulphate | Ciraparantag |
| Low molecular weight heparin | Protamine sulphate | Andexanet alfa, Ciraparantag |
| Fondaparinux | Consider recombinant activated factor VII | Andexanet alfa, Ciraparantag |
| Dabigatran | Idarucizumab | Ciraparantag |
| Factor Xa inhibitors | Four-factor PCC | Andexanet alfa, Ciraparantag |
PCC = prothrombin complex concentrate